Smith & Nephew Plc Notice of Results (5711F)
15 Luglio 2019 - 5:00PM
UK Regulatory
TIDMSN.
RNS Number : 5711F
Smith & Nephew Plc
15 July 2019
Timing of Smith & Nephew Second Quarter Trading and First
Half 2019 Results
15 July 2019
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical
technology business, will announce its second quarter trading and
first half 2019 results for the period ended 30 June 2019 on
Wednesday 31 July 2019 at 7.00am BST / 2.00am EDT. This will be
followed by a conference call for financial analysts at 8.30am BST
/ 3.30am EDT, details of which can be found on the Smith &
Nephew website at www.smith-nephew.com/results.
Enquiries
Investors/ Analysts
Andrew Swift +44 (0) 1923 477433
Smith & Nephew plc
Media
Charles Reynolds +44 (0) 1923 477314
Smith & Nephew plc
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business
that exists to restore people's bodies and their self-belief by
using technology to take the limits off living. We call this
purpose 'Life Unlimited'. Our 16,000+ employees deliver this
mission every day, making a difference to patients' lives through
the excellence of our product portfolio, and the invention and
application of new technologies across our three global franchises
of Orthopaedics, Advanced Wound Management and Sports Medicine
& ENT. Founded in Hull, UK, in 1856, we now operate in more
than 100 countries, and generated annual sales of $4.9 billion in
2018. Smith & Nephew is a constituent of the FTSE100 (LSE:SN,
NYSE:SNN). For more information about Smith & Nephew, please
visit www.smith-nephew.com and follow us on Twitter, LinkedIn,
Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORXELFFKDFBBBV
(END) Dow Jones Newswires
July 15, 2019 11:00 ET (15:00 GMT)
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Apr 2023 a Apr 2024